Dissertation > Excellent graduate degree dissertation topics show

Study on Recent Efficacy of Hydroxycamptothecin-based Combined Chemotherapy in Advanced Gastric Cancer

Author: LiHong
Tutor: FanQingXia；QinYanRu
School: Zhengzhou University
Course: Oncology
Keywords: Advanced gastric cancer Hydroxycamptothecin Chemotherapy
CLC: R735.2
Type: Master's thesis
Year: 2007
Downloads: 55
Quote: 0
Read: Download Dissertation

Abstract

Objective: Gastric cancer is one of our mortality was higher in malignant tumor found mostly in the late unresectable opportunity, clinical and more chemotherapy as a primary treatment. As with other malignancies, the design of advanced gastric cancer chemotherapy generally use two different mechanisms of action of chemotherapy drug combination, specific drugs that the joint cell cycle of the cell cycle non-specific drugs. Cisplatin (DDP) is the most common cell cycle non-specific drugs (CCNSA). The plant alkaloids hydroxycamptothecin (HCPT) in recent years, the rapid development of the cell cycle-specific drugs (CCSA). This study was based hydroxycamptothecin (HCPT) combined with chemotherapy in the treatment of advanced gastric cancer patients with curative effects and toxicity. MATERIALS AND METHODS: 119 patients with advanced gastric cancer patients were randomly divided into a treatment group and the control group, 59 cases of the treatment group, the control group of 60 patients, TNM stage Ⅲ patients with 51 cases, Ⅳ of 68 patients. Initial treatment of 53 patients, 66 cases of patients with retreatment. Treatment group programs: HCPT 10mg intravenous infusion of 1 to 5 days, 1 to 5 days ,5-FU 500mg / m ~ 2 infusion CF 100 mg intravenous 2h 2 ~ 3h 1 to 5 days, DDP 30mg / m ~~ bolus of 1 to 3 days. Control group program: CF 100mg intravenous 2h infusion days 1 to 5 ,5-FU 500mg / m ~ 2 2 ~ 3h 1 to 5 days, DDP 30mg / m ~~ 2 bolus 1 to 3 days. The two programs were 1 cycle of 21 days, after 3 cycles comprehensive review to evaluate the efficacy and toxicity analysis. Objective response evaluation in accordance with the National Cancer Institute of the U.S. National Cancer Institute (NCI) in Solid Tumors Response Evaluation Criteria (Response Evaluation Criteria in Solid Tumors, RECIST) is divided into: ① complete remission (CR): all target lesions disappeared, maintain more than four weeks. ② partial remission (PR): of target lesions longest diameter of and compared with the baseline state reduced by at least 30%. ③ stable lesions (SD): between partial response and disease progression. ④ disease progression (PD): target lesion longest diameter of and after the beginning of and treatment records to the minimum of the longest diameter of target lesion and compared with an increase of 20% or there is one or more new lesions. Effective standards: CR PR. Toxicity of chemotherapy drugs reference NCI common toxicity criteria (Common Toxicity Criteria, CTC) four-level classification is divided into 0 ~ Ⅳ grade. Toxicity in terms of the number of cycles of chemotherapy. Statistical Methods: The rate used to compare x ~ 2 test, all statistics are completed with SPSS11.0, the inspection level α = 0.05. Results: Recent efficacy in the treatment group total effective rate was 47.5% (28/59), Ⅲ period efficiency of 50.0% (13/26) of IV efficiency of 45.5% (15/33); total efficiency of the control group was 28.3% (17/60), Ⅲ of efficiency of 24.1% (7/29), Ⅳ period was 32.3% (10/31). The total effective rate x ~ 2 test (x ~~ 2 = 4.63, P <0.05), the difference was statistically significant; efficient Ⅲ of cases in the two groups by x ~ 2 test (x ~ 2 = 3.96, P <0.05 ), the difference was statistically significant; Ⅳ of cases in the two groups efficient x ~ 2 test (x ~~ 2 = 1.17, P> 0.05), the difference was not statistically significant. The two groups of cases of de novo efficient x ~ 2 test (x ~ 2 = 2.27, P> 0.05), no significant difference between the two groups of retreatment cases efficient x ~ 2 test (x ~~ 2 = 2.92, P > 0.05), the difference was not statistically significant. The two groups of patients with six-month survival rate by x ~ 2 test (x ~ 2 = 6.19, P <0.05), the difference was statistically significant. The toxicity treatment group, 59 patients received a total of 283 cycles of chemotherapy, the control group of 60 patients received a total of 289 cycles of chemotherapy, the main toxicities were nausea, vomiting, diarrhea, leukopenia, thrombocytopenia, hemoglobin decreased, abnormal liver function, kidney dysfunction and ECG abnormalities and oral mucosa Yandeng,. The results showed that the number of cycles of chemotherapy between the two groups leukopenia x ~ 2 test the difference was statistically significant (P <0.05). The rest toxicities occurred by x ~ 2 test the difference was not statistically significant. Two groups of patients were not serious toxicity, were restored to normal after symptomatic treatment, did not affect the treatment. Conclusion: containing HCPT combination chemotherapy in the treatment of advanced gastric cancer can significantly improve the efficiency and increase the survival rate of patients, while no obvious increase in adverse reactions, suitable for patients with advanced gastric cancer treatment.

Study on Recent Efficacy of Hydroxycamptothecin-based Combined Chemotherapy in Advanced Gastric Cancer

Abstract

Related Dissertations